RSS

European Commission (EC)

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a positive opinion to Akcea Therapeutics’ volanesorsen for the treatment of familial chylomicronaemia syndrome (FCS) under the Early Access to Medicines Scheme (EAMS). more

News

The European Commission (EC) has approved Roche’s routine prophylactic treatment in people with haemophilia A with factor VIII inhibitors, Hemlibra (emicizumab). more

News

The European Commission (EC) has revealed its decision to grant conditional marketing authorisation to Kyowa Kirin for Crysvita (burosumab) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children & adolescents more

Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. more

News

GlaxoSmithKline (GSK) has announced that its once-daily single inhaler triple therapy, Trelegy Ellipta, for the treatment of chronic obstructive pulmonary disease (COPD) has been granted marketing authorisation by the European Commission. more

Technology

The European Biopharmaceutical Enterprises (EBE) and European Federation of Pharmaceutical Industries and Associations (EFPIA) have issued a statement calling on the EC to improve transparency on hospital exemptions for advanced therapies. more

News

The European Commission (EC) has granted orphan designation to Apogenix’s lead product candidate, asunercept (APG101), for the treatment of myelodysplastic syndromes (MDS). more

News

The European Commission (EC) has granted marketing authorisation to Sanofi and Regeneron Pharmaceuticals for dupilumab (Dupixent) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. more

News

Janssen has announced that the European Commission (EC) has approved its darunavir-based single-tablet regimen (STR), Symtuza▼, for the treatment of HIV-1 in adults and adolescents in Europe. more

News

Biotech company, VAXIMM, has received orphan designation from the European Commission (EC) and the US Food and Drug Administration (FDA) for its lead product candidate, VXM01, for the treatment of glioma. more

News

The European Commission (EC) has approved Samsung Bioepis’ Imraldi — a biosimilar referencing adalimumab (Humira) — for the treatment of 10 inflammatory conditions. more

News

Dermatology specialist, LEO Pharma, has announced that the European Commission (EC) has granted marketing authorisation for its new biologic, Kyntheum (brodalumab), for the treatment of moderate-to-severe plaque psoriasis in adults within the EU. more

News

The European Commission (EC) has sent Teva Pharmaceuticals a statement of objections concerning its agreement with Cephalon, which has been preliminarily concluded as in breach of antitrust rules. more

News

The European Commission (EC) has awarded Antares Vision, provider of serialisation-based track and trace solutions for the pharma industry, a grant for the development of new technology for the inspection of lyophilised injectables. more

News

Merck has confirmed receipt of a Statement of Objections from the European Commission (EC) related to a packaging technology in development by Sigma-Aldrich, at the time it was acquired in 2015. more

News

Sanofi and Regeneron Pharmaceuticals have announced that the European Commission (EC) has granted marketing authorisation of Kevzara in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults more

News

The European Commission (EC) has granted marketing authorisation for Servier’s Lonsurf for the treatment of patients with advanced metastatic colorectal cancer (mCRC) more

News

With Valentines Day over and Easter fast-approaching, the second month of the year is already drawing to a close. We take a look at our most read stories from the last month. Two down and ten more to go… more

Opinion

The European Commission (EC) has approved Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) more

News